<DOC>
	<DOCNO>NCT00298909</DOCNO>
	<brief_summary>The investigator want study relative effect physical exercise vs. extended-release niacin ( lipid-lowering drug ) patient coronary heart disease low HDL cholesterol ( `` good cholesterol '' ) - lipid profile - endothelial function measure ultrasound The endothelium inner part blood vessel . Impaired endothelial function know associated atherosclerosis ultimately lead disease stroke , heart attack others . Endothelial function assess non-invasively ultrasound . Both intervention mention show beneficial effect lipid profile endothelial function . However , relative effect unclear .</brief_summary>
	<brief_title>Exercise Versus Niacin Patients With Coronary Artery Disease ( CAD ) Low High-Density Lipoproteins ( HDL )</brief_title>
	<detailed_description>Comparison physical exercise vs. extended-release niacin patient CAD low HDL cholesterol ( &lt; 1,03 mmol/L ) lipid profile endothelial function measure flow-mediated dilatation radial artery . Secondary goal assessment biochemical marker atherosclerosis , expression monocyte surface marker , oxidative stress thrombogenicity .</detailed_description>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Hypolipoproteinemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Coronary disease Low HDL cholesterol Age limit ( see ) Unstable angina oder MI within 3 month prior inclusion CAD indication bypass surgery Left main disease ( &gt; 25 % stenosis diameter ) Ejection fraction &lt; 40 % Higher degree heart valve disease Higher degree ventricular arrhythmia Type 1 Diabetes Severe disorder lipoprotein metabolism ( Lowdensity lipoprotein cholesterol ( LDL ) &gt; 5.0 mmol/L ) Severe liver disease Thyroid disease Alcohol drug abuse Pregnancy Stroke Transient Ischemic Attack ( TIA ) within 3 month prior inclusion Allergy niacin oder ingredient niaspan Participation clinical trial within 30 day prior inclusion Acute gastric ulcer Arterial bleeding Uncontrolled severe arterial hypertension Treatment lipidlowering drug HydroxyMethylglutaryl Coenzyme A ( HMGCoA ) inhibitor within 3 month prior inclusion</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>